Haven Life (MassMutual) Life Insurance After Breast Cancer Fit Review

Research Snapshot

Why Haven Life (MassMutual) Qualified for This Study

Questions This Section Answers

• Why did Haven Life (MassMutual) qualify for a life insurance after breast cancer review when only 3 of 7 platforms named it?
• Is Haven Life (MassMutual) worth considering for a breast cancer survivor who needs medically underwritten term coverage?

Haven Life (MassMutual) qualified because three platforms — anthropic, deepseek, and grok — named it during ranking discovery, meeting the minimum-mention threshold of two. Its qualification rests on the parent insurer's documented breast-cancer underwriting history rather than on Haven Life's own digital platform. MassMutual revised its underwriting guidelines for breast cancer survivors in 2011, incorporating updated staging and clinical subtypes of invasive breast cancer to produce more favorable offers for some survivors ^[1]. MassMutual also introduced broader guidelines to make life insurance more available to cancer survivors generally ^[5].

Haven Life is wholly owned by MassMutual, which holds an A++ (Superior) rating from AM Best ^[6]. That financial-strength link is the main reason the entity appears in a breast-cancer survivor discussion at all: the underwriting appetite sits with MassMutual, while the Haven Life brand supplies the digital application path.

The qualification is not a quality endorsement. Platform agreement that an entity is worth considering does not prove it will approve, rate, or price any particular survivor favorably. The ranking-stage identity detail for Haven Life was reported but its official domain was not independently verified during retrieval, and the official-site retrieval for havenlife.com returned an HTTP 403 failure, so no official page excerpt was captured ^[9].

The Product, Model, Plan, or Service Most Relevant to Life Insurance After Breast Cancer

Questions This Section Answers

• Which Haven Life (MassMutual) product should a breast cancer survivor apply for — Haven Term or Haven Simple?
• Does Haven Simple's no-exam path accept applicants with a prior breast cancer diagnosis?

The most relevant product is Haven Term, a medically underwritten level term policy issued by MassMutual or, for certain simplified-issue products, C.M. Life ^[10]. Haven Term has historically been described with term lengths of 10, 15, 20, 25, or 30 years and advertised coverage up to $3 million for eligible applicants ^[12]. Haven Simple is the no-medical-exam alternative, described as a 100% no-exam term product with lower coverage limits than Haven Term ^[12].

For a breast-cancer survivor, the critical product distinction is that the no-exam path is generally closed. Haven Life's own eligibility guidance indicates that a history of cancer requires full underwriting and is not eligible for the no-exam Haven Simple path ^[14]. That means the buyer would be evaluated on cancer type and stage, treatment received, and time since treatment rather than screened through a simplified questionnaire ^[14].

MassMutual separately offers term and whole life products through standard medical underwriting, which can accommodate some cancer histories with possible rate-classification adjustments ^[16]. MassMutual's published underwriting material describes a case study of a 56-year-old stage 1 survivor more than 10 years past mastectomy and chemotherapy, and presents a risk-factor table distinguishing favorable from less favorable criteria ^[17]. Buyers needing permanent coverage, cash value, or lifetime protection would generally need to apply through MassMutual directly or another carrier, because the cited Haven Life materials focus on term products and state that Haven Life does not sell certain permanent-policy categories ^[18].

What the AI Platforms Agreed About

Questions This Section Answers

• Do AI platforms agree that Haven Life (MassMutual) requires full medical underwriting for breast cancer survivors?
• Is MassMutual's breast cancer underwriting history a reason to choose Haven Life (MassMutual)?

Agreement was strong on three points and mixed on the entity's overall fit.

First, platforms agreed that a cancer history routes the applicant into full medical underwriting rather than a no-exam path. OpenAI reported that Haven Term underwriting may include an application, third-party data, a medical exam, and an attending physician statement ^[20]. DeepSeek reported that Haven Life's eligibility page states cancer history requires the fully underwritten Haven Term product ^[21]. Anthropic reported that applicants with complex medical histories are routed to traditional MassMutual underwriting rather than the InstantTerm algorithm ^[22]. Perplexity reported that Haven Term is medically underwritten and some applicants may need a medical exam ^[23].

Second, platforms agreed that MassMutual has a documented history of breast-cancer-specific underwriting revisions. Anthropic, grok, and google all cited the 2011 guideline revision incorporating updated staging and clinical subtypes ^[24]. Kimi cited MassMutual's published underwriting material showing capacity to offer Standard rates to selected survivors with favorable profiles ^[28].

Third, platforms agreed that approval, rate class, and premium are case-by-case and not publicly guaranteed. OpenAI, deepseek, perplexity, and kimi all stated that no public breast-cancer-specific eligibility table or pricing exists ^[29].

On overall fit, six of seven platforms rated Haven Life a mixed fit and one — google — rated it weak because it reported the platform is closed to new business ^[30]. That split is the central disagreement in this study.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Is Haven Life (MassMutual) still accepting new life insurance applications in 2026?
• Does Haven Life (MassMutual) publish breast-cancer-specific underwriting criteria for stage, grade, or receptor status?

The largest conflict is operational status. Google reported that Haven Life stopped accepting new applications on January 12, 2024, issued its final policies on March 31, 2024, and that legacy policies are now serviced directly by MassMutual, citing a wind-down driven by high customer acquisition costs and limited adoption ^[32]. Anthropic cited a November 2025 source stating Haven Life stopped accepting new applications January 12, 2024, while also citing a 2026 source claiming Haven Life issued 847,000 policies in 2026 with 94% instant no-exam approvals ^[34]. Grok likewise reported the January 2024 halt ^[36]. OpenAI, deepseek, perplexity, and kimi did not report a closure and described active products and application paths ^[37].

This conflict is unresolved in the supplied evidence. Buyers must confirm current availability directly before relying on any Haven Life application path.

The second uncertainty is underwriting transparency. No platform found a public breast-cancer-specific underwriting guide, eligibility table, or waiting-period schedule from Haven Life ^[41]. Perplexity noted that one third-party source describes Haven Term Simplified as available up to $500,000 without a medical exam, but that detail was not confirmed on Haven's own pages ^[43]. Kimi noted that whether Haven Simple's health questions allow any breast cancer history or automatically decline certain responses is unclear from public sources ^[40].

The third uncertainty is receptor status. Independent sources state that breast-cancer underwriting has evolved to incorporate molecular subtype information and receptor status, and that breast cancer is a collection of distinct molecular subtypes with different long-term risk profiles ^[44]. Kimi reported that underwriting varies by molecular subtype but that MassMutual's published materials do not explicitly detail receptor status as a factor ^[46].

A fourth uncertainty concerns the age of the guideline evidence. MassMutual's publicly documented breast-cancer guideline revisions date to 2011, and no platform located current 2026 guidelines ^[48]. Whether modern underwriting still reflects those favorable ratings, or has since been tightened, is not established by the supplied evidence.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What underwriting factors does Haven Life (MassMutual) consider for a breast cancer survivor applying for term coverage?
• Does Haven Life (MassMutual) offer conversion to permanent coverage without new medical underwriting?

Haven Life's stated cancer underwriting approach considers cancer type, stage, treatment history, and recovery dates, and describes tumor size and grade as potentially relevant ^[51]. That is directionally consistent with the buyer's stated criteria, but the cited material does not specifically confirm review of receptor status, recurrence history, or surveillance results for every applicant ^[51].

Medical underwriting for Haven Term may include a paramedical examination and an attending physician statement, and the assigned rate class affects the offered policy and price ^[53]. Haven Life advertises online applications, real-time data review, and possible immediate eligibility decisions, though applicants with complex medical histories may still require additional records, an examination, or extended underwriting ^[52]. Anthropic reported that the InstantTerm algorithm queries MIB records, prescription databases, motor vehicle records, and public data in real time, and that healthy applicants under 60 with no significant medical history can receive a binding decision in minutes without a paramedical exam ^[54]. Cancer survivors typically fall outside that simple-profile group ^[56].

On conversion, anthropic reported that Haven Term includes a standard conversion option to MassMutual permanent coverage available until age 65 or the end of the term, whichever comes first, without additional medical underwriting ^[56]. This is a platform-reported term detail, not a verified contract term, and should be confirmed in the issued policy.

On product structure, Haven Term is level-premium term insurance, and premiums are intended to remain level during the selected term ^[57]. Coverage ends at the end of the term unless a continuation or conversion provision applies, and post-term premiums may be substantially higher ^[57]. Haven Life's terms state that approval is not guaranteed, eligibility depends on underwriting guidelines, and products may not be available in every state ^[58]. Anthropic reported that Haven Life is not available in New York state ^[56].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Haven Life (MassMutual) cost per month for a breast cancer survivor, and are there setup or cancellation fees?
• What flat-extra or table-rating charges might a breast cancer survivor pay on a Haven Term policy?

No platform verified a current premium for a breast-cancer survivor. OpenAI stated that individual pricing for a survivor is unclear without an application and underwriting review, and that public Haven Life examples are historical estimates for applicants in excellent health ^[59]. DeepSeek stated that Haven Life does not publish cancer-specific pricing and that a history of breast cancer can result in standard, rated, or declined offers ^[61]. Perplexity reported a Haven site example of a 35-year-old woman buying $500,000 for 20 years at $17.50 per month, and a review source reporting a $250,000 20-year starting point of $14.99 per month, while noting these do not reflect survivor underwriting ^[62].

Platform-reported cost ranges for survivors vary widely. Anthropic reported flat-extra premiums of $750 or more per $100,000 of coverage for five or more years post-treatment in some cases, depending on stage, and reported MassMutual standard term rates near average for $100,000–$250,000 policies but 15–17% above national average for $500,000+ policies ^[64]. Kimi reported standard rates for a favorable 10-year-plus survivor at roughly $40–$80 per month per $100,000 of term coverage, table ratings adding roughly 75–100% above standard at Table C–D, and flat extras such as $3.50 per $1,000 (about $1,750 per year on a $500,000 policy), typically temporary ^[66]. Kimi also reported that applicants with identical profiles can receive offers varying by 200–300% between carriers ^[66].

On fees, no platform verified an application fee, policy fee, or medical exam fee for this use case ^[67]. OpenAI stated that a required paramedical examination is generally described as paid by the insurer, subject to confirmation ^[60]. Anthropic reported no disclosed hidden fees for Haven Term and noted that the Haven Life Plus rider is included in policy cost without separate itemization ^[68].

On contract terms, premiums for level-term coverage are intended to remain level during the selected term, and coverage ends at term expiration unless a continuation or conversion provision applies ^[60]. Anthropic reported a free-look period typically of 10–14 days and no explicit cancellation penalty ^[68]. Kimi reported a standard two-year contestability period applies to all policies and that misrepresentation of cancer history voids a claim ^[66]. These contract details are platform-reported and should be confirmed in the issued policy.

Pricing confidence across platforms was low to moderate. No platform produced a survivor-specific quote, and the supplied evidence does not establish what a breast-cancer survivor would actually pay.

Best Suited For

Questions This Section Answers

• Who is Haven Life (MassMutual) best suited for among breast cancer survivors seeking term life insurance?
• Is Haven Life (MassMutual) a good choice for an early-stage, long-term breast cancer survivor with documented surveillance?

Haven Life is best suited to a survivor whose treatment ended several years ago, with no recurrence, who can complete full medical underwriting and wants level term coverage ^[69]. OpenAI described the best-considered group as applicants seeking affordable level-term coverage rather than permanent insurance, comfortable with medical underwriting and possible paramedical examination, and whose treatment is completed with well-documented recurrence-free status and available surveillance records ^[69].

Anthropic described a narrower best-fit group: survivors age 45 or younger who completed treatment five or more years ago with no recurrence and qualify for standard or preferred ratings, and survivors of early-stage (stage 1), hormone receptor-positive breast cancer with favorable prognostic factors ^[71]. Kimi described long-term survivors (10+ years) with early-stage (stage 0–1), node-negative, grade 1 disease in full remission as the strongest candidates, citing MassMutual's published case study ^[72].

Buyers who want to check eligibility and get an initial quote online, and who are willing to complete a medical exam and records review, are also in the target group ^[70]. Buyers open to MassMutual's standard underwritten term or whole life if the digital path is declined or rated should treat that as the realistic fallback ^[73].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Haven Life (MassMutual) for life insurance after breast cancer?
• Is Haven Life (MassMutual) a poor fit for a survivor in active treatment or with metastatic disease?

Haven Life is probably not best suited to survivors in active treatment, with recent diagnosis, or with metastatic, recurrent, or advanced-stage disease ^[75]. DeepSeek listed active treatment or recent diagnosis, metastatic or recurrent or advanced-stage disease, a preference for no-exam or guaranteed-acceptance coverage, and a priority on comparing many carriers before committing as poor-fit situations ^[75].

Anthropic listed survivors with recent diagnosis or active treatment, applicants over 60, survivors needing whole life or permanent coverage with cash value, and those with stage 3+ disease or complex treatment histories seeking more than $3 million in coverage as poor-fit groups ^[77]. Kimi listed applicants needing guaranteed issue with no health questions, those seeking coverage above simplified-issue caps without full medical underwriting, and survivors wanting an immediate full death benefit without an exclusion period ^[78].

Buyers who want an independent broker to compare multiple carriers' breast-cancer underwriting before submitting an application are also poorly served by a single-brand path ^[79]. Perplexity listed survivors needing clearly documented breast-cancer-specific underwriting guidelines before applying and buyers who likely need guaranteed issue or a carrier known publicly for impaired-risk underwriting as poor-fit groups ^[80].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Haven Life (MassMutual) for a breast cancer survivor who needs guaranteed-issue coverage?
• When should a breast cancer survivor apply directly through MassMutual instead of Haven Life?

Another option may be better in four recurring situations.

When the buyer needs guaranteed-issue or simplified-issue coverage. Guaranteed-issue products with no health questions and two- to three-year graded benefit periods are available from other carriers, typically capped at $25,000 for ages 45–80 ^[81]. Haven Life does not appear to offer guaranteed issue ^[81].

When the buyer needs permanent coverage. Haven Life focuses on term products and does not offer certain permanent-policy categories, so a buyer needing lifelong coverage, cash value, or estate-planning-oriented permanent insurance may need to apply directly through MassMutual or another carrier ^[83]. MassMutual offers whole life policies with lifelong coverage and cash value accumulation, but MassMutual does not provide online quotes or applications and requires a financial professional ^[84].

When the buyer wants comparative underwriting before applying. An independent broker with access to multiple carriers can shop breast-cancer underwriting before a formal application is submitted ^[86]. Grok named Lincoln Financial or Protective for breast cancer history and Mutual of Omaha or similar for guaranteed issue as alternatives per independent reviews ^[88]. Anthropic named Pacific Life, Prudential, or Guardian as carriers with more flexible underwriting and explicit cancer survivor programs for survivors over 60 with complex histories ^[89]. These alternative names are platform-reported and were not independently verified in this study.

When the buyer wants an active digital-first experience. Google stated that if the buyer wants an active digital-first life insurance experience, active providers such as Ethos or Ladder may be better, and that a buyer wanting to leverage MassMutual's specific breast cancer underwriting guidelines should apply directly through a MassMutual agent or independent broker ^[90].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Haven Life (MassMutual) before signing a life insurance contract after breast cancer?
• Which insurer will issue the policy, and what underwriting class or rating would apply?

Confirm operational status first. Ask whether Haven Life is currently accepting new life insurance applications, given the conflict between the reported January 2024 halt and later sources describing active sales ^[91].

Confirm the issuing carrier. Ask which insurer will issue the policy in the buyer's state — MassMutual, C.M. Life, or another entity — because Haven Life product disclosures identify MassMutual and C.M. Life as issuing carriers for specified products and state that forms and features may vary by state ^[94].

Confirm the underwriting pathway. Ask whether the buyer is eligible for Haven Term, Haven Simple, both, or neither given the cancer history, and whether the application will be routed to traditional MassMutual underwriting ^[96].

Confirm the underwriting factors. Ask how stage, grade, tumor size, receptor status, genetic findings if applicable, surgery, chemotherapy, radiation, endocrine therapy, recurrence history, and current surveillance will affect the decision ^[98].

Confirm the timing rules. Ask what minimum time since treatment completion is required and whether ongoing endocrine therapy counts as active treatment ^[98].

Confirm the documentation. Ask whether an attending physician statement, oncology records, pathology report, imaging, or surveillance results will be required ^[101].

Confirm the rating outcome. Ask what underwriting class, rating table, postponement period, exclusion, or coverage limit would apply if approved, and what flat-extra amount and duration would attach ^[98].

Confirm pre-application options. Ask whether an informal or preliminary underwriting assessment is available before submitting a formal application ^[98].

Confirm the contract terms. Ask about current term lengths, maximum face amounts, conversion rights, renewal terms, riders, free-look period, and state-specific limitations ^[105].

Confirm the final price. Ask for the final premium after underwriting rather than the initial online estimate ^[106].

Confirm the decline consequences. Ask whether a decline or postponement will be reported to the Medical Information Bureau or affect applications elsewhere ^[98].

Final AI Consensus Verdict

Mixed fit. Six of seven platforms rated Haven Life (MassMutual) a mixed fit for life insurance after breast cancer, and one rated it weak on the basis that the direct-to-consumer platform is closed to new business ^[107]. The strongest evidence in Haven Life's favor is MassMutual's documented history of revising breast-cancer underwriting guidelines and its A++ financial-strength backing ^[109]. The strongest evidence against is that the no-exam path is closed to cancer histories, full medical underwriting is required, and no public breast-cancer-specific eligibility table or survivor pricing exists ^[112].

The unresolved operational-status conflict is material. A buyer cannot act on this review without first confirming whether Haven Life is accepting new applications at all. If it is not, the practical path is MassMutual's standard agency channel or another carrier.

Platform agreement here reflects convergent retrieval, not verified product quality. No platform produced a survivor-specific quote, and no platform independently verified the other platforms' claims. Buyers should obtain a preliminary comparison through an independent broker and verify the exact underwriting treatment, issuing carrier, current product availability, and final rated premium before purchasing ^[113].

How This Review Was Produced

This review was produced from a structured multi-platform research run dated 2026-09-22 covering seven platforms: openai, anthropic, deepseek, grok, kimi, perplexity, and google. Each platform was asked which life insurance carriers are generally worth considering for applicants with a history of breast cancer, and each returned fit findings, strengths, limitations, pricing notes, and verification questions for Haven Life (MassMutual).

Haven Life (MassMutual) was named by three of the seven platforms during ranking discovery — anthropic, deepseek, and grok — at ranks 10, 8, and 5 respectively, for an average listed rank of 7.67 and a best listed rank of 5. It met the minimum-mention threshold of two and was carried into the fit-review stage, where all seven platforms evaluated it.

Citations in this review are platform-reported evidence, not independently verified facts. Company-owned sources are labeled as owned in the Sources section; independent sources are labeled as independent. No personal testing, customer experience, or independent verification was performed for this review.

Methodology Limitations

Several limitations apply.

Platform-reported research dates differ from the authoritative run date. DeepSeek reported a research date of 2026-06-01, while the run research date is 2026-09-22 (platform_date_discrepancies). Platform-reported dates are provenance metadata and do not independently prove freshness.

One platform ran without search enabled. DeepSeek reported search_enabled as false, so its claims rest on model knowledge rather than retrieved sources and require explicit verification before being described as current facts (research_capabilities).

The official-site retrieval failed. The official fact-source retrieval for havenlife.com returned an HTTP 403 failure with no captured excerpts, so no official page content was verified for this review (official_fact_sources).

The supplied URLs were collected from platform responses and were not independently validated by the writer stage. A source URL is not proof that a claim was verified.

The operational-status conflict is unresolved. Platforms disagree on whether Haven Life is accepting new applications, and this review does not resolve that conflict.

The breast-cancer underwriting evidence is dated. MassMutual's publicly documented guideline revisions date to 2011, and no current 2026 guidelines were located.

No survivor-specific pricing was verified. All cost figures in this review are platform-reported ranges or historical examples for healthy applicants.

Identity normalization notes apply. Official-site retrieval failed for one or more mentions, no failed fetch was used as a verified domain key, identity used exact-name fallback with the matching reported domain retained but unverified, and company-name variants were collapsed onto one canonical brand before minimum-mentions qualification (normalization_notes).